CLINICAL TRIALS PROFILE FOR BMS-986165

Clinical Trials for BMS-986165

Trial ID	Title	Status	Sponsor	Phase	Summary
NCT02534636 ↗	Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis	Completed	Bristol-Myers Squibb	Phase 1	The purpose of this study is to establish if BMS-986165 is safe and effective at treating autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for inhibiting autoimmune conditions. This study will be the first time this drug is given to humans, and will be conducted entirely in healthy subjects. It will be run in 4 Parts. Part A will investigate single oral doses of drug. Part B will investigate giving the drug daily for 14 days. Part C will investigate daily doses for 14 days in healthy volunteers with Japanese decent. Part D will investigate whether food, stomach acidity or giving the drug in a capsule makes a difference to the safety and potential use of this drug.
NCT02931838 ↗	Study to Evaluate Effectiveness and Safety in Subjects With Moderate to Severe Psoriasis	Completed	Bristol-Myers Squibb	Phase 2	A Study to evaluate efficacy and safety in subjects with moderate to severe Psoriasis treated with BMS-986165
NCT03004768 ↗	Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants	Completed	Covance	Phase 1	An oral dose in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986165
NCT03004768 ↗	Pharmacokinetics and Metabolism of [14C]BMS-986165 in Healthy Male Participants	Completed	Bristol-Myers Squibb	Phase 1	An oral dose in healthy subjects to obtain information about the absorption, metabolism, and excretion (AME) of BMS-986165
NCT03252587 ↗	An Investigational Study to Evaluate BMS-986165 in Participants With Systemic Lupus Erythematosus	Active, not recruiting	Bristol-Myers Squibb	Phase 2	This study will investigate BMS-986165 to assess its effects in participants with systemic lupus erythematosus (SLE).
NCT03254784 ↗	A Study to Evaluate BMS-986165 Tablet Formulation Relative to BMS-986165 Capsule Formulation and the Effect of a High-Fat/ High-Calorie Meal and Increased Gastric pH on the BMS-986165 Tablet Formulation	Completed	Bristol-Myers Squibb	Phase 1	The purpose of this study is to evaluate BMS-986165 tablet formulation versus BMS-986165 capsule formulation. This study will also evaluate the effect of a high-fat/ high-calorie meal and increased gastric pH on the BMS-986165 tablet formulation.

Clinical Trial Conditions for BMS-986165

Condition Name

Condition Name
Intervention	Trials
Psoriasis	13
Healthy Participants	11
Systemic Lupus Erythematosus	6
Psoriatic Arthritis	3

Condition MeSH

Condition MeSH
Intervention	Trials
Psoriasis	16
Lupus Erythematosus, Systemic	7
Arthritis, Psoriatic	6
Colitis	3

Clinical Trial Locations for BMS-986165

Trials by Country

Trials by Country
Location	Trials
United States	345
Japan	133
China	75
Canada	53
Australia	48

Trials by US State

Trials by US State
Location	Trials
Florida	18
California	17
New York	16
Texas	16
Pennsylvania	14

Clinical Trial Progress for BMS-986165

Clinical Trial Phase

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 4	2
Phase 3	11
Phase 2	13

Clinical Trial Status

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	30
Recruiting	14
Not yet recruiting	5

Clinical Trial Sponsors for BMS-986165

Sponsor Name

Sponsor Name
Sponsor	Trials
Bristol-Myers Squibb	52
Covance	1
Beth Israel Deaconess Medical Center	1

Sponsor Type

Sponsor Type
Sponsor	Trials
Industry	53
Other	2